Feasibility trial of Darwin OncoTreat and OncoTarget precision medicine testing to improve outcomes for patients with limited metastatic disease that failed first-line systemic therapy.

PLoS One · 2025 · PMC12157055 · PMID 40498747

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The endpoint was 30-day disease control based on single agent activity with OncoTarget (68%) and OncoTreat (91%) both highly significant with the predicted drugs outperforming control of selected antineoplastic drugs [ 19 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.